• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Anlotinib for Refractory Advanced Non-Small Cell Lung Cancer in China.

作者信息

Chen Xin-Zu

机构信息

Department of Gastrointestinal Surgery & Laboratory of Gastric Cancer, West China Hospital, Sichuan University, Chengdu, China.

出版信息

JAMA Oncol. 2019 Jan 1;5(1):116-117. doi: 10.1001/jamaoncol.2018.5526.

DOI:10.1001/jamaoncol.2018.5526
PMID:30489609
Abstract
摘要

相似文献

1
Anlotinib for Refractory Advanced Non-Small Cell Lung Cancer in China.安罗替尼在中国用于难治性晚期非小细胞肺癌的治疗。
JAMA Oncol. 2019 Jan 1;5(1):116-117. doi: 10.1001/jamaoncol.2018.5526.
2
Clinical outcomes and safety of osimertinib plus anlotinib for patients with previously treated EGFR T790M-positive NSCLC: A retrospective study.奥希替尼联合安罗替尼治疗经治 EGFR T790M 阳性 NSCLC 患者的临床疗效和安全性：一项回顾性研究。
J Clin Pharm Ther. 2022 May;47(5):643-651. doi: 10.1111/jcpt.13591. Epub 2022 Jan 12.
3
Fingerprint loss during combination therapy using osimertinib and anlotinib: A case report.使用奥希替尼和安罗替尼联合治疗期间指纹缺失：一例报告。
J Clin Pharm Ther. 2022 Feb;47(2):248-250. doi: 10.1111/jcpt.13480. Epub 2021 Jul 8.
4
Cost-effectiveness of Osimertinib vs Docetaxel-bevacizumab in Third-line Treatment in EGFR T790M Resistance Mutation Advanced Non-Small Cell Lung Cancer in China.奥希替尼对比多西他赛联合贝伐珠单抗三线治疗表皮生长因子受体 T790M 耐药突变的晚期非小细胞肺癌在中国的成本效果分析。
Clin Ther. 2020 Nov;42(11):2159-2170.e6. doi: 10.1016/j.clinthera.2020.08.018. Epub 2020 Oct 4.
5
Comments on Cost-Effectiveness of Osimertinib for EGFR Mutation-Positive Non-Small-Cell Lung Cancer after Progression during First-Line EGFR Tyrosine Kinase Inhibitor Therapy.奥希替尼用于一线表皮生长因子受体酪氨酸激酶抑制剂治疗期间进展后的表皮生长因子受体突变阳性非小细胞肺癌的成本效益评论
J Thorac Oncol. 2018 May;13(5):e83-e84. doi: 10.1016/j.jtho.2018.02.006.
6
Response: Comments on Cost-Effectiveness of Osimertinib for EGFR Mutation-Positive Non-Small Cell Lung Cancer after Progression following First-Line EGFR Tyrosine Kinase Inhibitor Therapy.回应：关于奥希替尼用于一线表皮生长因子受体酪氨酸激酶抑制剂治疗进展后的表皮生长因子受体突变阳性非小细胞肺癌的成本效益评论
J Thorac Oncol. 2018 May;13(5):e84-e85. doi: 10.1016/j.jtho.2018.02.017.
7
China National Medical Products Administration approval summary: anlotinib for the treatment of advanced non-small cell lung cancer after two lines of chemotherapy.中国国家药品监督管理局批准概要：安罗替尼用于二线化疗后治疗晚期非小细胞肺癌。
Cancer Commun (Lond). 2019 Jun 20;39(1):36. doi: 10.1186/s40880-019-0383-7.
8
Concurrent use of anlotinib overcomes acquired resistance to EGFR-TKI in patients with advanced EGFR-mutant non-small cell lung cancer.安罗替尼克服了晚期 EGFR 突变型非小细胞肺癌患者对 EGFR-TKI 的获得性耐药。
Thorac Cancer. 2021 Oct;12(19):2574-2584. doi: 10.1111/1759-7714.14141. Epub 2021 Sep 12.
9
Cost-Effectiveness Analysis of Anlotinib as Third- or Further-Line Treatment for Relapsed Small Cell Lung Cancer (SCLC) in China.安罗替尼作为三线或后线治疗中国复发性小细胞肺癌（SCLC）的成本效益分析。
Adv Ther. 2021 Oct;38(10):5116-5126. doi: 10.1007/s12325-021-01889-2. Epub 2021 Aug 21.
10
[Chinese expert consensus on Anlotinib Hydrochloride for advanced lung cancer (2020 edition)].《盐酸安罗替尼治疗晚期肺癌中国专家共识（2020年版）》
Zhonghua Zhong Liu Za Zhi. 2020 Oct 23;42(10):807-816. doi: 10.3760/cma.j.cn112152-20200721-00669.

引用本文的文献

1
Whole-Brain Radiotherapy Simultaneous Integrated Boost Intensity-Modulated Radiotherapy Combined With Anlotinib in the Treatment of Brain Metastases.全脑放疗同步整合加量调强放疗联合安罗替尼治疗脑转移瘤
Cancer Control. 2025 Jan-Dec;32:10732748251319489. doi: 10.1177/10732748251319489.
2
Efficacy and safety of anlotinib combined with S‑1 as a third‑ or later‑line treatment for advanced non‑small cell lung cancer in China: A systematic review and meta‑analysis.安罗替尼联合S-1作为中国晚期非小细胞肺癌三线及以上治疗的疗效和安全性：一项系统评价和荟萃分析
Oncol Lett. 2024 Oct 14;28(6):613. doi: 10.3892/ol.2024.14746. eCollection 2024 Dec.
3
Anlotinib reversed resistance to PD-1 inhibitors in recurrent and metastatic head and neck cancers: a real-world retrospective study.
安罗替尼逆转复发性和转移性头颈部癌对 PD-1 抑制剂的耐药性：一项真实世界的回顾性研究。
Cancer Immunol Immunother. 2024 Aug 6;73(10):199. doi: 10.1007/s00262-024-03784-5.
4
Oral Anlotinib Maintenance Therapy for an Advanced Malignant Peritoneal Mesothelioma Diagnosed by Laparoscopy After Initial Misdiagnosis to Obtain Longer Progression-Free Survival: Case Report and Literature Review.口服安罗替尼维持治疗对初始误诊后经腹腔镜诊断的晚期恶性腹膜间皮瘤患者获得更长无进展生存期：病例报告及文献复习
Onco Targets Ther. 2023 Nov 15;16:961-972. doi: 10.2147/OTT.S430190. eCollection 2023.
5
Anlotinib plus icotinib as a potential treatment option for EGFR-mutated advanced non-squamous non-small cell lung cancer with concurrent mutations: final analysis of the prospective phase 2, multicenter ALTER-L004 study.安罗替尼联合伊可替尼作为伴有合并突变的 EGFR 突变型晚期非鳞状非小细胞肺癌的潜在治疗选择：前瞻性、多中心、ALTER-L004 研究的最终分析。
Mol Cancer. 2023 Aug 5;22(1):124. doi: 10.1186/s12943-023-01823-w.
6
Current status and future of anti-angiogenic drugs in lung cancer.肺癌抗血管生成药物的现状与未来。
Clin Exp Med. 2023 Oct;23(6):2009-2023. doi: 10.1007/s10238-023-01039-8. Epub 2023 Mar 15.
7
Anlotinib Exerts Inhibitory Effects against Cisplatin-Resistant Ovarian Cancer In Vitro and In Vivo.安罗替尼在体外和体内对顺铂耐药卵巢癌均具有抑制作用。
Molecules. 2022 Dec 14;27(24):8873. doi: 10.3390/molecules27248873.
8
METTL3 suppresses anlotinib sensitivity by regulating mA modification of FGFR3 in oral squamous cell carcinoma.在口腔鳞状细胞癌中，METTL3通过调节FGFR3的m⁶A修饰来抑制安罗替尼敏感性。
Cancer Cell Int. 2022 Sep 27;22(1):295. doi: 10.1186/s12935-022-02715-7.
9
Effective low-dose Anlotinib induces long-term tumor vascular normalization and improves anti-PD-1 therapy.有效低剂量安罗替尼诱导长期肿瘤血管正常化并改善抗 PD-1 治疗。
Front Immunol. 2022 Aug 3;13:937924. doi: 10.3389/fimmu.2022.937924. eCollection 2022.
10
Retrospective Review of Efficacy and Safety of Anlotinib in Advanced Leiomyosarcoma: A Real-World Study.安罗替尼治疗晚期平滑肌肉瘤的疗效与安全性回顾性分析：一项真实世界研究
Cancer Manag Res. 2022 May 11;14:1703-1711. doi: 10.2147/CMAR.S357334. eCollection 2022.